|
GSK PLC on Monday announced that Japan’s Ministry of Health, Labour & Welfare expanded the eligible population for its respiratory syncytial virus vaccine Arexvy. The London-based pharmaceutical company said Japan has allowed the inoculation of people aged 18 to 49 at increased risk for RSV disease. Prior to the approval, the vaccine had already been allowed for people aged 60 and over, and for 50 to 59-year-olds at increased risk for RSV. The approval is based on phase 3b trial data which showed a non-inferior immune response in adults aged 18 to 49 at increased risk for RSV compared to adults aged 60 years and above. ‘This expanded approval, the first covering all at-risk adults in Japan, can help reduce potentially severe outcomes of RSV. It recognises the serious impact RSV can have for adults of any age living with chronic conditions such as cardiovascular disease, chronic obstructive pulmonary disease and asthma, and it enables more people to take a proactive approach to disease prevention,’ said Sanjay Gurunathan, GSK Head of Vaccines & Infectious Diseases Research & Development. GSK shares were 0.1% higher at 1,863.50 pence each on Monday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
